Autoinjectors Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032

The Autoinjectors Market Size accounted for USD 51.3 Billion in 2022 and is estimated to achieve a market size of USD 248.6 Billion by 2032 growing at a CAGR of 17.4% from 2023 to 2032.

Autoinjectors Market Highlights

• Global autoinjectors market revenue is poised to garner USD 248.6 Billion by 2032 with a CAGR of 17.4% from 2023 to 2032
• North America autoinjectors market value occupied around USD 21 billion in 2022
• Asia-Pacific autoinjectors market growth will record a CAGR of more than 18% from 2023 to 2032
• Among usage type, the disposable autoinjectors sub-segment generated over US$ 32 billion revenue in 2022
• Based on route of administration, the intramuscular sub-segment generated around 58% share in 2022
• Increasing implementation of wearable autoinjectors is a popular market trend that fuels the industry demand

Autoinjectors, also known as auto-injectors, are medical devices designed to deliver a dose of a drug through the subcutaneous or intramuscular route of administration. They were initially created to overcome hesitation associated with self-administration of needle-based drug delivery devices. These devices are easy to use and are intended for self-administration by patients or administration by untrained personnel. Moreover, the size of the injection is dependent on the drug loaded. Essentially, an autoinjector is a syringe with a pre-loaded dosage of the drug and a spring-charged needle. With the help of this device, consumers can self-administer the dosage of the drug.

Global Autoinjectors Market Dynamics

Market Drivers

• Benefits of auto-injectors in emergency medical care
• Rising incidence of diabetes and anaphylaxis
• Patients preference to choose self-administration of injections

Market Restraints

• Modes of alternative medication delivery
• High cost of auto injectors

Market Opportunities

• The requirement to limit patient visits and physical contact
• Increasing shift to therapy to home setting

Autoinjectors Market Report Coverage

Autoinjectors Market Insights

The auto-injectors market is gaining growth on account of the growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing the number of regulatory approvals, availability of generic versions of auto-injectors, favorable reimbursements and government support in developed and some developing economies, and increasing preference for self-administration due to ease of use. The increasing demand for prefilled and disposable auto-injectors due to their handiness, less probability of infection, and ease of use is further bolstering the market value. Furthermore, fundamental shifts from biologics to biosimilars, which are delivered through auto-injectors are factors anticipated to create potential opportunities over the forecast period from 2023 to 2032.

In contrast, the availability of alternative drug delivery modes, ongoing research, development, and launch of oral diabetic agents and oral insulin, and development of nasal epinephrine sprays are some of the prominent factors expected to hinder auto injectors market growth over the forecast period.

Autoinjectors Market Segmentation

The worldwide market for autoinjectors is split based on therapy, usage type, route of administration, end-user, and geography.

Autoinjectors Market, By Therapies

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other Therapies

Autoinjectors, when categorized by therapy segment, include rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. According to the autoinjectors industry analysis, the anaphylaxis therapy sub-segment dominates the market and holds the largest market share, which was nearly 37% in the past years. The prevalence of serious allergies and reactions due to various reasons such as food allergies and chronic diseases like allergic asthma has been increasing, leading to a rise in allergy-related health issues. These factors are expected to drive the auto-injectors market growth of the anaphylaxis therapy segment in the future years.

Autoinjectors Market, By Usage Types

• Disposable Autoinjectors
• Reusable Autoinjectors

Within the usage type segment, the autoinjectors are categorized into two types: disposable autoinjectors and reusable autoinjectors. The disposable autoinjectors subsegment has held the largest market share in recent years and is anticipated to continue its dominance. Reusable autoinjectors consist of two parts - prefilled and empty autoinjectors. Disposable autoinjectors are highly convenient for both patients and healthcare providers, designed for one-time use only. Additionally, disposable autoinjectors offer high safety features and help minimize needle injuries, which are key factors contributing to the growth of the auto injectors market.

Autoinjectors Market, By Route of Administrations

• Subcutaneous
• Intramuscular

The auto-injectors market, based on the route of administration, is segmented into two types: subcutaneous and intramuscular. The subcutaneous segment accounted for the largest market share in recent years. This subsegment is primarily used for various medications' delivery. Autoinjectors designed for subcutaneous administration ensure reliable absorption and help maintain therapeutic drug levels over a prolonged period, offering consistent and accurate medication delivery. These autoinjectors are specially designed for patients to effectively self-administer their medications in the comfort of their homes.

Autoinjectors Market, By End-Users

• Home Care Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

Home care settings accounted for the major revenue share in the global autoinjectors market. By end-use, the home care settings segment is experiencing increased demand in the global market. The bolstering demand for auto-injectors in home care settings especially from the developing economies is supporting the increased spending power of people on healthcare devices. The ease of use associated with the auto-injectors is ultimately increasing the demand for auto-injectors in-home care.

Autoinjectors Market, By Regions

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Autoinjectors Market Regional Analysis

North America accounted for the maximum revenue share in the autoinjectors market. In 2022, North America leads the auto-injectors market with maximum revenue share, and the region is also projected to maintain its dominance over the forecast period from 2023 to 2032. The increasing incidences of anaphylaxis, the growing prevalence of diabetes, rheumatoid arthritis, and other ailments, additionally the presence of residents with high disposable income are the factors supporting the regional market value. Moreover, the US and Canada are major contributors to the regional market value. The autoinjectors are often used in the US military to protect personnel from chemical warfare agents. Atropine and 2-PAM-Cl (pralidoxime chloride) are used for first aid against nerve agents.

Asia Pacific is anticipated to exhibit the fastest auto injectors market growth during the estimated period from 2023 to 2032. The developing economies of the Asia Pacific region are projected to support their fastest growth over the forecast period from 2023 to 2032. The increasing disposable income and number of people with the demand for therapies that use auto-injectors is further boosting the market growth. The rising prevalence of type 1 diabetes due to changing lifestyles and rapid urbanization is supporting the growth. Moreover, in China, around 50,000 children & adolescents below 20 years of age were living with type 1 diabetes in past few years and the number has increased after that.

Autoinjectors Market Players

Some of the top autoinjectors companies offered in our report includes AbbVie, Inc., Amgen, Biogen Idec, Eli Lilly, Johnson & Johnson, Mylan N.V., Owen Mumford, Pfizer, Inc., Sanofi, Scandinavian Health Ltd., Teva Pharmaceutical, Ypsomed, and others.